Harvard Bioscience Regains Compliance with NASDAQ's Continued Listing Requirements
HOLLISTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced today that it received written notification from NASDAQ (the "Notice") stating the Company has regained compliance with NASDAQ's Listing Rule 5250(c)(1) and the matter is now closed.
On March 17, 2016, the Company announced that it had received a letter from NASDAQ stating that the Company was in violation of Listing Rule 5250(c)(1) because it failed to timely file its Annual Report on Form 10-K for the fiscal year ended on December 31, 2015 and that the Company had until May 16, 2016 to submit a plan of compliance to NASDAQ. On May 3, 2016, the Company received written notification from NASDAQ that it had regained compliance with Listing Rule 5250(c)(1) upon its filing of such Annual Report on Form 10-K on April 29, 2016.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including GE Healthcare, Thermo Fisher Scientific Inc., VWR and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
For investor inquiries, please call (508) 893-8999. Press releases may be found on our web site.
CONTACT: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999 Fax: 508 429 8478